Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,925.00
Bid: 1,925.00
Ask: 1,927.00
Change: -10.00 (-0.52%)
Spread: 2.00 (0.104%)
Open: 1,938.00
High: 1,942.00
Low: 1,924.00
Prev. Close: 1,935.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Blocklisting Interim Review

6 Apr 2016 16:11

RNS Number : 4108U
Hikma Pharmaceuticals Plc
06 April 2016
 

 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

Date: 6 April 2016

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From:

1 October 2015

To:

31 March 2016

Balance of unallotted securities under scheme(s) from previous return:

SOP: 846,700 ordinary shares of 10 pence

LTIP: 44,000 ordinary shares of 10 pence

MIP: 103,102 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 600,000 ordinary shares of 10 pence

MIP: 200,000 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 41,500 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 988 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 805,200 ordinary shares of 10 pence

LTIP: 644,000 ordinary shares of 10 pence

MIP: 302,114 ordinary shares of 10 pence

     

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2015

-

-

846,700

Blocklisting return 01/10/15

04/11/2015

0

17,500

829,200

 

15/12/2015

0

20,000

809,200

 

23/12/2015

0

4,000

805,200

Blocklisting return on 01/04/16

 

 

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2015

-

-

44,000

Blocklisting return 01/10/15

23/10/2015

600,000

0

644,000

Blocklisting return on 01/04/16

 

 

 

Management Incentive Plan ("MIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2015

-

-

103,102

Blocklisting return 01/10/15

23/10/2015

200,000

0

303,102

 

08/12/2015

0

605

302,497

 

08/01/2016

0

383

302,114

Blocklisting return on 01/04/16

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRGMGGDKVLGVZM
Date   Source Headline
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights
30th Oct 20179:26 amRNSHikma launches Pantoprazole Sodium for Injection
5th Oct 20179:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.